Investment Rating - The report assigns a "Buy" rating for the stock, indicating that it is expected to outperform the benchmark by more than 15% within the next six months [10]. Core Insights - The company has achieved significant revenue growth, with a 403.83% year-on-year increase in revenue to 517 million yuan in the first half of 2025, and a net profit of 83 million yuan, marking a turnaround from a loss of 1.237 billion yuan in the same period of 2024 [2]. - The drug discovery solutions segment saw a remarkable 615% increase in revenue, reaching 435 million yuan, driven by strategic collaborations and advancements in AI technology [2]. - The intelligent automation solutions segment also performed well, with a 95.9% increase in revenue to 82 million yuan, showcasing the effectiveness of AI and robotics in chemical processes [2]. Financial Performance Summary - Revenue projections for the company are as follows: 2024A: 266 million yuan, 2025E: 693 million yuan, 2026E: 984 million yuan, and 2027E: 1.337 billion yuan, reflecting a growth rate of 53%, 160%, 42%, and 36% respectively [4]. - The net profit forecast shows a recovery from a loss of 1.517 billion yuan in 2024A to a profit of 39 million yuan in 2025E, with further increases to 86 million yuan in 2026E and 184 million yuan in 2027E [4]. - The earnings per share (EPS) is projected to improve from -0.79 yuan in 2024A to 0.01 yuan in 2025E, 0.02 yuan in 2026E, and 0.05 yuan in 2027E [4]. Business Segment Performance - The drug discovery solutions segment is highlighted for its strong performance, with significant partnerships and awards enhancing its market position [2]. - The intelligent robotics solutions segment is noted for its innovative applications in chemical processes, achieving high success rates and operational efficiency [2]. - The company is leveraging AI and robotics to create a multi-dimensional innovation ecosystem, enhancing its capabilities in drug development and chemical research [2].
晶泰控股（02228）：业绩大幅提升，AI药物研发进入新阶段